XML 40 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue from Contracts with Customers (Tables)
6 Months Ended
Jun. 30, 2021
Schedule of Contract Assets and Contract Liabilities

Total contract assets at June 30, 2021 were as follows:

 

(In thousands)

 

Contract Assets

 

Contract assets at December 31, 2020

 

$

19,401

 

Additions

 

 

18,152

 

Transferred to receivables, net

 

 

(23,760

)

Contract assets at June 30, 2021

 

$

13,793

 

Total contract liabilities at June 30, 2021 were as follows:

 

(In thousands)

 

Contract Liabilities

 

Contract liabilities at December 31, 2020

 

$

23,909

 

Additions

 

 

 

Amounts recognized into revenue

 

 

(3,108

)

Contract liabilities at June 30, 2021

 

$

20,801

 

Product sales, net  
Schedule of Disaggregation of Revenues

During the three and six months ended June 30, 2021 and 2020, the Company recorded product sales, net, as follows:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

(In thousands)

 

2021

 

 

2020

 

 

2021

 

 

2020

 

VIVITROL

 

$

88,417

 

 

$

71,646

 

 

$

162,951

 

 

$

150,415

 

ARISTADA and ARISTADA INITIO

 

 

72,391

 

 

 

58,769

 

 

 

127,820

 

 

 

109,726

 

Total product sales, net

 

$

160,808

 

 

$

130,415

 

 

$

290,771

 

 

$

260,141

 

Manufacturing and royalty revenues  
Schedule of Disaggregation of Revenues

During the three and six months ended June 30, 2021 and 2020, the Company recorded manufacturing and royalty revenues as follows:

 

 

 

Three Months Ended June 30, 2021

 

 

Six Months Ended June 30, 2021

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

 

$

 

 

$

81,072

 

 

$

81,072

 

 

$

 

 

$

142,642

 

 

$

142,642

 

VUMERITY

 

 

6,724

 

 

 

13,624

 

 

 

20,348

 

 

 

9,172

 

 

 

24,616

 

 

 

33,788

 

RISPERDAL CONSTA

 

 

12,003

 

 

 

2,448

 

 

 

14,451

 

 

 

22,686

 

 

 

5,927

 

 

 

28,613

 

AMPYRA/FAMPYRA

 

 

7,549

 

 

 

5,767

 

 

 

13,316

 

 

 

15,627

 

 

 

12,361

 

 

 

27,988

 

Other

 

 

3,017

 

 

 

10,090

 

 

 

13,107

 

 

 

6,893

 

 

 

22,217

 

 

 

29,110

 

 

 

$

29,293

 

 

$

113,001

 

 

$

142,294

 

 

$

54,378

 

 

$

207,763

 

 

$

262,141

 

 

 

 

 

Three Months Ended June 30, 2020

 

 

Six Months Ended June 30, 2020

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

 

$

 

 

$

69,385

 

 

$

69,385

 

 

$

 

 

$

124,312

 

 

$

124,312

 

VUMERITY

 

 

1,305

 

 

 

1,289

 

 

 

2,594

 

 

 

2,632

 

 

 

1,654

 

 

 

4,286

 

RISPERDAL CONSTA

 

 

10,193

 

 

 

3,536

 

 

 

13,729

 

 

 

33,776

 

 

 

7,269

 

 

 

41,045

 

AMPYRA/FAMPYRA

 

 

7,154

 

 

 

5,354

 

 

 

12,508

 

 

 

14,976

 

 

 

12,501

 

 

 

27,477

 

Other

 

 

6,689

 

 

 

11,600

 

 

 

18,289

 

 

 

14,168

 

 

 

21,468

 

 

 

35,636

 

 

 

$

25,341

 

 

$

91,164

 

 

$

116,505

 

 

$

65,552

 

 

$

167,204

 

 

$

232,756